

MINUTES OF 26th MEETING OF THE TECHNICAL COMMITTEE HELD ON 26.06.2015 UNDER THE CHAIRMANSHIP OF DGHS FOR SUPERVISING CLINICAL TRIALS ON NEW CHEMICAL ENTITIES IN THE LIGHT OF DIRECTIONS OF THE HON'BLE SUPREME COURT OF INDIA ON 03.01.2013.

Present:

1. Dr. Jagdish Prasad, Chairman
Director General of Health Services,
Nirman Bhawan, New Delhi
2. Dr. Nikhil Tandon, Member
Professor, Dept. of Endocrinology & Metabolism,
AIIMS, New Delhi.
3. Dr. B.L. Sherwal, Member
Addl. MS (T) & Director-Professor,
Dept. of Microbiology,
LHMC & Associated Hospitals, New Delhi.

From CDSCO:

1. Dr. G. N. Singh
Drugs Controller General of India
2. Dr. V. G. Somani,
Joint Drugs Controller (I)
3. Mrs. Annam Visala
Deputy Drugs Controller (I)
4. Mrs. Rubina Bose
Deputy Drugs Controller (I)

Dr. G.N Singh DCG (I) welcomed the members of the meeting and initiated the proceedings of the Committee.

It was decided by DGHS, Chairman to defer all the proposals to the next Technical Committee as most of the members of the Committee were not able to attend the meeting. However, it was also decided by DGHS that two firms who were invited for representation of their cases, may be allowed to deliver their proposals.

Accordingly following two proposals were discussed.

1. Representation by M/s Ipca Laboratories Ltd for waiver of Phase IV trial of the drug Hydroxychloroquine Sulfate tablet 300mg based on the recommendation of the Committee in its 25th Meeting.

M/s Ipca Laboratories Ltd had applied for the grant of permission to manufacture and market Hydroxychloroquine Sulfate Tablet 300mg for the treatment of patients with lower body weight i.e 45-60kg in rheumatoid arthritis, Systemic lupus erythematosus & polymorphic light eruption.

Earlier, the drug, Hydroxychloroquine sulphate 200mg has been approved on 9.9.01 for manufacturing and marketing for the treatment of rheumatoid arthritis and subsequently approved on 13.10.2006 for systemic lupus erythematosus & polymorphic light eruption as additional indication. Hydroxychloroquine sulphate, 400mg was also approved on 31.01.2008 as additional strength for above mentioned indication.

Thereafter, the firm applied for the grant of permission to manufacture and market Hydroxychloroquine Sulfate Tablet 300mg.

Accordingly, the proposal was deliberated in NDAC (Anaesthetic & Rheumatology), (Now renamed as SEC) on 19.02.2014. The Committee opined that the proposed strength of 300mg may be given for the patients with lower body weight i.e 45 -60kg. The Committee opined that Phase IV trial protocol shall be submitted within 6 months. As per the NDAC recommendation the firm was given permission on 08-09-2014 for the above mentioned indication with the condition of conducting of Phase IV clinical trial.

Thereafter, the firm requested this Directorate to consider waiver to conduct Phase IV trial and the proposal was deliberated in SEC (Analgesic, Anaesthetic & Rheumatology) held on 23-01-2015. The Committee recommended that firm should conduct phase- IV clinical trial within the stipulated time.

Then firm again submitted a request letter to this Directorate to consider waiver of conducting Phase IV trial for above formulation.

Accordingly, the proposal was deliberated in 25th Technical Committee meeting held on 28-06-2015 wherein the Committee opined that firm may be requested to make a presentation before the Committee to decide further for considering Phase IV clinical trial waiver.

Accordingly, firm was requested to present their proposal before the Committee

Recommendation of the Technical Committee:

The firm made detailed presentation before the Committee for waiver of Phase-IV Clinical trial of the drug Hydroxychloroquine Sulfate Tablet 300mg. The firm presented two published international clinical studies on the use of Hydroxychloroquine Sulfate Tablet 300mg strength. The Committee noted that Hydroxychloroquine Sulfate Tablet 200mg and 400mg are already approved in the country and Hydroxychloroquine Sulfate Tablet 300mg is an intermediate dose for the treatment of patients with body weight between 45-60 kg who are unable to take higher dose due to toxicity. The Committee also noted that Hydroxychloroquine Sulfate Tablet 300mg will minimize the retinal toxicity associated with Hydroxychloroquine in such patients.

After deliberation, the Committee recommended for waiver of Phase IV clinical trial. However the firm should conduct active post marketing surveillance and submit the data to the office of DCG (I) for further review.

2. Representation by M/s Novartis Ltd for Phase- III trial permission with LCZ696 as per the recommendation of the 25th Technical Committee.

M/s Novartis Ltd had applied for the grant of permission of phase III clinical trial with LCZ696 titled “A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696”

The proposal was examined by the Subject Expert Committee (SEC) and detail of deliberation is placed below:

- **SEC recommendation dated 26-02-2015:**

After detailed deliberation the committee opined that the protocol should include base line data of patient, CRF should include Echo Cardiographic assessment at base line and all follow up. Accordingly revised CRF and protocol should be submitted to this office for further review.

- **SEC recommendation dated 01-05-2015:**

The firm expressed their inability to conduct Echo Cardiography assessment at base line and at follow up, as more than 150 patients have already been recruited in the study and it is difficult to amend global protocol. After detailed deliberation the committee approved the existing protocol.

Accordingly, the proposal was deliberated in 25th Technical Committee meeting held on 28-05-2015 wherein Committee recommended that the applicant shall make detail presentation before the Committee.

Accordingly firm was directed to present their proposal before the Committee.

Recommendation of the Technical Committee:

The firm made detailed presentation before the Committee. After deliberation, the Committee opined that the firm may be asked to represent the justification for no requirement of any baseline test and submit protocol approved by USFDA in the forthcoming Technical Committee meeting. Also cardiologist shall be invited for their expert opinion regarding the baseline and follow up test for further decision.

The meeting ended with vote of thank to the Chair.
